LCC In Italian--First-Line Treatment Options for EGFR Mutant NSCLC
Lung Cancer Considered
by IASLC
2d ago
This episode of Lung Cancer Considered discusses first-line treatment options for EGFR mutant NSCLC, in Italian. Guest: Dr. Jessica Menis is a thoracic medical oncologist with expertise in early-phase trials and drug development from Azienda Ospedaliera Universitaria Integrata Verona. Jessica, welcome to the podcast. Guest: Professor Filippo de Marinis is from Istituto Europeo di Oncologia, where he is Direttore della Divisione di Oncologia Toracica, and the president of Associazione Italiana Oncologia Toracica ..read more
Visit website
FDA Approval Of Tarlartamab
Lung Cancer Considered
by IASLC
2d ago
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recently approved bispecific T-cell engager, tarlatamab, for small cell lung cancer. Guest: Dr. Anne-Marie Dingemans is a pulmonologist and Professor of Thoracic Oncology at Erasmus Medical Center in Rotterdam, the Netherlands. Guest: Dr.Ryan Gentzler is an Associate Professor and Director of the Thoracic Oncology Clinical Research Program at the University of Virginia ..read more
Visit website
ASCO 2024 Summary Part 2
Lung Cancer Considered
by IASLC
1w ago
In episode two summarizing important lung cancer data presented at ASCO 2024, Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu cover the phase III CROWN trial, ROS1 NSCLC with a novel ROS1 TKI, taletrectinib, the MARIPOSA trial, the PALOMA-3 trial, the WU-KONG1 data, the BEAMION-Lung1 trial, and CheckMate 77T. Guest: Dr. Clarissa Mathias is the Director of NOB/Oncoclinicas in Brazil, a member of the ASCO International Quality Steering Group and Lung Cancer Committee, and a previous IASLC Board Member. Guest: Dr. Delvys Rodriguez-Abreu is the Head of Medical Oncology at Hospi ..read more
Visit website
IASLC - ASCO 2024 Summary--Part 1
Lung Cancer Considered
by IASLC
1w ago
Title: ASCO 2024 Highlights Part 1 - Plenary Description: ASCO 2024 had so much lung cancer data, two podcast episodes are required to cover all the data presented. In this first episode, hosts Dr. Stephen Liu and Dr. Narjust Florez cover the LAURA trial, the ADAURA trial, the KRYSTAL-12 study, the phase III EVOKE-01 trial, the phase III ADRIATIC trial, and the REACH-PC trial. Guest: Dr. David Spigel is the Chief Scientific Officer at Sarah Cannon Research Institute and recipient of the IASLC Heine H. Hansen Lectureship for SCLC. Guest: Dr. Lecia Sequist is the Program Director for Cancer Earl ..read more
Visit website
Updates in CT Screening for Lung Cancer
Lung Cancer Considered
by IASLC
2w ago
Host Dr. Stephen Liu moderates a discussion of lung cancer screening using low dose CT scans. Low dose CT scans have been shown to detect lung cancer earlier and significantly improve lung cancer mortality. Yet they remain underutilized and are only being used to detect certain types of lung cancer, specifically, smoking-related lung cancer. Guest: Dr. Pan-Chyr Yang is a Professor and former President of National Taiwan University College of Medicine and recipient of the IASLC Joseph W. Cullen Prevention & Early Detection Award at the 2020 WCLC. Guest: Dr. Elaine Shum is an Assistant Profe ..read more
Visit website
LCC and Smoking Cessation
Lung Cancer Considered
by IASLC
3w ago
May 31st is World No Tobacco Day and to observe this, Lung Cancer Considered host Dr. Narjust Florez leads a discussion on smoking cessation and how to honor the need for smoking cessation counseling without contributing to stigma. Smoking tobacco products (primarily cigarettes) is an important risk factor for the development of lung cancer and secondhand smoke is also a significant cause of lung cancer. Worldwide, smoking accounts for approximately two-thirds of lung cancer cases ..read more
Visit website
Lung Cancer Considered--Smoking Cessation
Lung Cancer Considered
by IASLC
3w ago
May 31st is World Tobacco Day and the IASLC podcast "Lung Cancer Considered" features a leading expert on smoking cessation, Dr. Kathryn Taylor. Dr. Taylor is behavioral scientist and a Professor in the Department of Oncology at the Georgetown Lombardi Comprehensive Cancer Center in Washington DC Smoking tobacco products (primarily cigarettes) is an important risk factor for the development of lung cancer. Secondhand smoke is also a significant cause of lung cancer. Worldwide, smoking accounts for approximately 2/3 of lung cancer cases with the remaining occurring due to other causes ..read more
Visit website
LCC in French Canadian
Lung Cancer Considered
by IASLC
1M ago
LCC in French Canadian by IASLC ..read more
Visit website
Virtual Tumor Board: PD-L1 Low NSCLC
Lung Cancer Considered
by IASLC
1M ago
In this virtual tumor board episode, host Dr. Stephen Liu leads a discussion about the management of metastatic, PD-L1 low NSCLC. Dr. Apar Ganti is a Professor of Medicine at the University of Nebraska Medical Center and the Associate Director for Clinical Research at the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska. Dr. Sze-Wai Chan from the Sandton Oncology Centre in Johannesburg, South Africa, where she is the Director and Head of Clinical Trial Research ..read more
Visit website
KRAS in NSCLC: Beyond G12C
Lung Cancer Considered
by IASLC
1M ago
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, other than G12C. This form of lung cancer varies by geography and incidence. KRAS mutations were once thought undruggable, but KRAS inhibitors are now available. However, not all forms of KRAS mutant lung cancers are the same and clinicians need to be aware of the difference between KRAS mutations ..read more
Visit website

Follow Lung Cancer Considered on FeedSpot

Continue with Google
Continue with Apple
OR